Current Report Filing (8-k)
May 24 2022 - 12:09PM
Edgar (US Regulatory)
0001582249 false 0001582249 2022-05-23
2022-05-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported):
May 23, 2022
RASNA THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
|
Nevada |
|
333-191083 |
|
39-2080103 |
|
(State or
other jurisdiction
of
incorporation)
|
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
|
420 Lexington Avenue,
Suite 2525,
New York,
NY
|
|
10170 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s telephone
number, including area code:
646-396-4087
(Former
name or former address, if changed since last report)
Copies
to:
Jeffrey
Fessler, Esq.
Sheppard,
Mullin, Richter & Hampton LLP
30
Rockefeller Plaza
New York,
New York 10112
Telephone:
(212) 653-8700
Facsimile:
(212) 653-8701
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Emerging
growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| |
|
|
|
|
Item
3.02 Unregistered
Sales of Equity Securities.
On May 23,
2022, Rasna Therapeutics, Inc. (the “Company”) issued 3,437,708
shares of the Company’s common stock to a consultant, issuable in
lieu of fees upon the conversion of certain convertible notes. The
issuance of the above securities were exempt from the registration
requirements of the Securities Act in reliance on the exemptions
afforded by Section 4(a)(2) of the Securities Act of 1933, as
amended.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: May
24, 2022
| |
RASNA
THERAPEUTICS, INC. |
| |
|
|
| |
By: |
/s/
Keeren Shah |
|
|
|
Name: |
Keeren
Shah |
| |
|
Title: |
Chief
Financial Officer |
-2-
Rasna Therapeutics (PK) (USOTC:RASP)
Historical Stock Chart
From Aug 2022 to Sep 2022
Rasna Therapeutics (PK) (USOTC:RASP)
Historical Stock Chart
From Sep 2021 to Sep 2022
